The company’s Phase I trial found that patients remained disease free after three months utilising the lowest doses of RAG-01 ...

The Department of Science and Technology (DOST), in partnership with the Nueva Vizcaya State University (NVSU), opened the ...

Ractigen Therapeutics, a clinical-stage biopharmaceutical company pioneering small activating RNA (saRNA) therapeutics, today announced the presentation of positive preliminary data from its ongoing ...

Wide Mineralized Intersection: The second RPM discovery hole (AN-24-03) returned an average of 0.25% nickel and 0.29% ...

RAG-01 is an innovative saRNA therapy designed to upregulate the p21 tumor suppressor gene ... via intravesical instillation using Ractigen's proprietary LiCO™ delivery technology, RAG-01 ...

RAG-01 is an innovative saRNA therapy designed to upregulate the p21 tumor suppressor gene, a key regulator of cell cycle progression that has been challenging to target with traditional therapies.

Repression of DREAM complex targets occurs independently of p21 under asynchronous conditions ... where p130 is predominantly expressed in the G0/G1 phase and p107 in the late G1/S/G2 phase (Grana et ...

With clinical trials results trickling in, “antiaging” drugs that clear away senescent cells are proving to be promising — ...